scispace - formally typeset
O

Owen S. Fenton

Researcher at Massachusetts Institute of Technology

Publications -  47
Citations -  3445

Owen S. Fenton is an academic researcher from Massachusetts Institute of Technology. The author has contributed to research in topics: Catalysis & In vivo. The author has an hindex of 22, co-authored 41 publications receiving 2295 citations. Previous affiliations of Owen S. Fenton include College of the Holy Cross & National University of Singapore.

Papers
More filters
Journal ArticleDOI

Advances in Biomaterials for Drug Delivery.

TL;DR: Advances in biomaterials for drug delivery are enabling significant progress in biology and medicine, including major breakthroughs in materials for cancer immunotherapy, autoimmune diseases, and genome editing.
Journal ArticleDOI

Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy

TL;DR: The lipid nanoparticle formulation presented here is a promising vector for mRNA vaccine delivery, one that is capable of inducing a strong cytotoxic T cell response and further optimization, including the incorporation of different adjuvants, will likely enhance the potency of the vaccine.
Journal ArticleDOI

Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs.

TL;DR: An optimized formulation which increased the potency of erythropoietin-mRNA-loaded C12-200 lipid nanoparticles 7-fold relative to formulations previously used for siRNA delivery and increased ionizable lipid:mRNA weight ratios was developed.
Journal ArticleDOI

Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity.

TL;DR: It is shown that lipidoid nanoparticles mediate potent gene knockdown in hepatocytes and immune cell populations upon IV administration to mice (siRNA EC50 values as low as 0.01 mg/kg); new design criteria that reliably predict in vivo siRNA delivery efficacy without any prior biological testing are described.
Journal ArticleDOI

Polymer-Lipid Nanoparticles for Systemic Delivery of mRNA to the Lungs.

TL;DR: The formulations were capable of functional delivery of mRNA to the lungs after intravenous administration in mice and are the first report of the systemic administration of mRNA for delivery to the lung using degradable polymer-lipid nanoparticles.